LUVOX (fluvoxamine maleate) by Jazz Pharmaceuticals is neurons. First approved in 2008.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
LUVOX (fluvoxamine maleate) is an oral selective serotonin reuptake inhibitor (SSRI) approved for psychiatric and obsessive-compulsive disorder indications. It works by potently inhibiting the serotonin reuptake transporter on neuronal membranes, increasing synaptic serotonin availability. The drug is a small-molecule tablet formulation marketed by Jazz Pharmaceuticals.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting teams are focused on market protection and managed decline strategies rather than growth initiatives.
neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
Worked on LUVOX at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LUVOX offers limited career growth opportunities given its LOE-approaching lifecycle and minimal linked job postings (0 identified). Roles focus on managing decline, pricing defense, and operational efficiency rather than innovation or expansion.